Scinai Immunotherapeutics Ltd. · NASDAQ:SCNI
Scinai Immunotherapeutics — BiondVax Pharmaceuticals — Investor Presentation (March 2021)
13 slides from Scinai Immunotherapeutics's investor presentation, Mar 22, 2021
Slide 1: BiondVax Pharmaceuticals Ltd Company Presentation
BiondVax Pharmaceuticals Ltd Company Presentation BiondVax Pharmaceuticals Ltd. | Jerusalem, Israel | www.biondvax.com www.biondvax.com March 2021
Slide 2: Safe Harbor Statement
S AFE H ARBOR S TATEMENT This presentation is not a prospectus or offer of securities for subscription or sale in any jurisdiction. All statements in this communication, other than those relating to historical facts, are "forward - looking statements" within the meaning of the United States Private
Slide 3: About BiondVax
A BOUT B IOND V AX About BiondVax Pharmaceuticals (NASDAQ: BVXV) is a biopharmaceutical company focused on development, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses. Experience Vaccine Development Founded 2005 . E
Slide 4: BiondVax's Mission and Vision
B IOND V AX ’ S M ISSION AND V ISION About To become a globally trusted and preferred bio - pharmaceutical company known for fast product development of highly innovative products, offering a reliable supply of high - quality and effective prophylactic and therapeutic products for infectious disease
Slide 5: Management
CSO & CMO ▪ PhD (Weizmann Institute of Science) ▪ Biotechnology General Ltd. ▪ Co - invented and guided BiondVax’s original vaccine candidate through 8 clinical trials including pivotal Phase 3 CFO ▪ BA Business (College of Administration) ▪ MBA (Bar Ilan University) ▪ Certified Public Accountant (C
Slide 6: Board of Directors
B OARD OF D IRECTORS Leadership CEO NeuroDerm Ltd (Senior Scientist), Novartis Vaccines USA (R&D and Global Supply chain) , GSK Vaccines Belgium (Global Supply Chain and Global Engineering) Mr. Amir Reichman Director Credit Suisse First Boston (Investment Banking), Private equity and venture capital
Slide 7: Scientific Advisory Board (SAB)
S CIENTIFIC A DVISORY B OARD (SAB) Leadership ID Biomedical (CSO), Intellivax (Founder), Walter Reed General Hospital (Consultant) Dr. George Lowell Biodar (CEO), Rodar (Founder), Israel Biotech Organization Professor Avner Rotman Former VP of Weizmann Institute. Coinventor of Copaxone®. Former Pres
Slide 8: BiondVax Value Proposition
B IOND V AX V ALUE P ROPOSITION Value Proposition BiondVax’s assets, capabilities and experiences position us well for in - licensing, acquisitions, and joint ventures & rapid clinical development and manufacturing of new infectious disease therapeutic and prophylactic technologies. Manufacturing, q
Slide 9: Planned Plans for 2021
PLANNED P LANS FOR 2021 Pipeline Development BiondVax is actively pursuing opportunities to develop its asset pipeline, with a focus on prevention and treatment of infectious diseases and related illnesses. Mr. Amir Reichman New CEO Asset pipeline opportunities assessment Raised $12.8m Asset pipelin
Slide 10: Manufacturing Facility
M ANUFACTURING F ACILITY : 10 - 40 M DOSE C APACITY May serve as pilot plant for larger drug substance facility BiondVax GMP Manufacturing Facility Area ~ 1850 m 2 ( 20,000 ft 2 ) Approved cGMP by Israel Ministry of Health (MOH) & EU QP Designed to meet FDA and EMA requirements Currently setup to pr
Slide 11: Modular & Agile GMP Manufacturing
M ODULAR & A GILE GMP M ANUFACTURING BiondVax GMP Manufacturing Facility Single - use equipment enables: Adaptable manufacturing processes and products Quicker manufacturing lead times for new products Agile response to emerging infectious disease threats Faster time - to - market for new vaccine an
Slide 12: Summary Financial Data & Cap Table
S UMMARY F INANCIAL D ATA & C AP T ABLE Financials CAP TABLE ADS Outstanding % Ordinary ADS 14,332,146 96% Options + RSUs 642,052 4% Fully Diluted Shares Outstanding 14,974,197 100% • Updated February 12 , 2021 • Voluntarily delisted from Tel Aviv Stock Exchange January 22 , 2018 . (ADS - Shares 1:4
Slide 13: Contact Information
BiondVax Pharmaceuticals Ltd BiondVax Pharmaceuticals Ltd. | Jerusalem, ISRAEL | www.biondvax.com Contact Information: Joshua Phillipson, Investor Relations j.phillipson@biondvax.com + 972 - 8 - 930 - 2529 www.biondvax.com
BiondVax Pharmaceuticals — Investor Presentation (March 2021) on 6ix